Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer’s disease, according to the federal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
